CAREER Act of 2025

500

119th Congress

In Committee

CAREER Act of 2025

Summary

Comprehensive Addiction Recovery through Effective Employment and Reentry Act of 2025 or the CAREER Act of 2025 This bill reauthorizes and expands programs to assist individuals in substance use disorder treatment and recovery to live independently and participate in the workforce. Specifically, the bill reauthorizes through FY2030 the Substance Abuse and Mental Health Services Administration (SAHMSA) Treatment, Recovery, and Workforce Support Grant Program, which provides employment training and recovery support services in coordination with state and local stakeholders. The bill further authorizes using 5% of such grant funds for transportation services and requires grantees to report on the employment and earnings outcomes of program participants. The bill also reauthorizes through FY20230 the Department of Housing and Urban Development (HUD) Recovery Housing Pilot Program, which assists states in providing individuals in recovery from a substance use disorder with stable, temporary housing for up to two years.

Lobbying filings that explicitly cite this bill (1)

These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.

Filing registrants (1)

LOGICAL DECORUM CAPITAL STRATEGIES, LLC (1)

DR. JOSE M. WILEYclient→LOGICAL DECORUM CAPITAL STRATEGIES, LLC

2026 · first_quarter · Government Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Communications with United States Senate offices and federal executive branch officials on behalf of Dr. Jose M. Wiley, MD, MPH, FACC, FSCAI, regarding federal health policy priorities and federal health agency matters. Engagement during the reporting period included meetings and communications with Senate offices on matters within the jurisdiction of the Senate Committee on Health, Education, Labor, and Pensions and the Senate Committee on Veterans Affairs; communications with officials at the Department of Health and Human Services regarding federal health policy priorities and potential positioning of Dr. Wiley for federal health engagement; written outreach to officials at the National Institutes of Health regarding federal health leadership matters and Dr. Wileys potential service in a senior federal health leadership capacity; and written outreach to the National Economic Council within the Executive Office of the President regarding healthcare economics, pharmaceutical pricing policy, and Dr. Wileys potential contribution to federal health policy deliberations. Policy discussions addressed chronic disease prevention, cardiovascular health, metabolic health, pharmaceutical pricing and pharmacy benefit manager reform, veterans health, nutrition and food policy, military medical readiness, and federal health agency reform. Specific legislation referenced during these communications included S.1587, the Fair Prescription Drug Prices for Americans Act; S.3822, the Break Up Big Medicine Act; S.1816, the Improving Seniors Timely Access to Care Act of 2025; S.3299, the DSH in Tennessee Act; and S.500, the CAREER Act of 2025. The engagement is framed around Dr. Wileys clinical expertise as a cardiologist, his academic and health system leadership, and his service as a Lieutenant Colonel in the United States Army Reserve, positioning his experience as a resource for federal health policymakers pursuing the priorities reflected in the administrations health reform agenda. The Senate office communications were collaborative and policy-oriented in nature, focused on shared legislative priorities in chronic disease prevention, veterans health, and federal health agency performance. No substantive meeting or advocacy regarding a specific Senate-confirmed position occurred during the reporting period.